Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077579743> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2077579743 endingPage "951" @default.
- W2077579743 startingPage "950" @default.
- W2077579743 abstract "The hallmarks of restless legs syndrome (RLS) are a desire to move the limbs due to sensory discomfort, motor restlessness, and worsening of symptoms during rest or at night.1 Sensory symptoms cause the greatest discomfort,2 and are commonly localized to muscle.Sensory and motor symptoms can be improved with dopaminergic medications, some anticonvulsants, opioids, and to a lesser extent with GABA-active hypnotics. Botulinum toxin has been suggested as a potential therapy for refractory RLS, based on its ability to reduce peripheral and central sensitization to pain.3 In an unblinded observational study by Rotenberg and colleagues, IM injections of 70–320 mouse units (mU) of botulinum toxin type A (BTX-A; Botox, Irvine, CA) were injected into the legs of three patients with RLS and demonstrated symptom improvement, reduced medication use, and a reduction in daytime sleepiness.4 Based on these findings, we conducted a randomized, placebo-controlled, double-blind, crossover study.### Methods.#### Patients.We enrolled six patients from June to July 2007 who were age 18 or older, had a diagnosis of primary RLS based on International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria,1 had a minimum score of 11 (at least moderate severity) on the IRLSSG rating scale (IRLS),5 and were stable on medications for greater than 6 weeks prior to enrollment. Patients were excluded for an abnormal neurologic examination, abnormal laboratory test results, a dermatologic disorder precluding leg injections, pregnancy/lactation, incapacity for informed consent, taking medications which could interact with BTX-A, …" @default.
- W2077579743 created "2016-06-24" @default.
- W2077579743 creator A5000787275 @default.
- W2077579743 creator A5005566965 @default.
- W2077579743 creator A5063493384 @default.
- W2077579743 date "2008-09-15" @default.
- W2077579743 modified "2023-10-16" @default.
- W2077579743 title "DOUBLE-BLIND, PLACEBO-CONTROLLED, PILOT TRIAL OF BOTULINUM TOXIN A IN RESTLESS LEGS SYNDROME" @default.
- W2077579743 doi "https://doi.org/10.1212/01.wnl.0000325994.93782.a1" @default.
- W2077579743 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2676942" @default.
- W2077579743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18794499" @default.
- W2077579743 hasPublicationYear "2008" @default.
- W2077579743 type Work @default.
- W2077579743 sameAs 2077579743 @default.
- W2077579743 citedByCount "19" @default.
- W2077579743 countsByYear W20775797432012 @default.
- W2077579743 countsByYear W20775797432013 @default.
- W2077579743 countsByYear W20775797432014 @default.
- W2077579743 countsByYear W20775797432015 @default.
- W2077579743 countsByYear W20775797432016 @default.
- W2077579743 countsByYear W20775797432018 @default.
- W2077579743 countsByYear W20775797432019 @default.
- W2077579743 countsByYear W20775797432021 @default.
- W2077579743 countsByYear W20775797432022 @default.
- W2077579743 countsByYear W20775797432023 @default.
- W2077579743 crossrefType "journal-article" @default.
- W2077579743 hasAuthorship W2077579743A5000787275 @default.
- W2077579743 hasAuthorship W2077579743A5005566965 @default.
- W2077579743 hasAuthorship W2077579743A5063493384 @default.
- W2077579743 hasBestOaLocation W20775797432 @default.
- W2077579743 hasConcept C118552586 @default.
- W2077579743 hasConcept C142724271 @default.
- W2077579743 hasConcept C16568411 @default.
- W2077579743 hasConcept C1862650 @default.
- W2077579743 hasConcept C204787440 @default.
- W2077579743 hasConcept C27081682 @default.
- W2077579743 hasConcept C2776750294 @default.
- W2077579743 hasConcept C2777478456 @default.
- W2077579743 hasConcept C2991744798 @default.
- W2077579743 hasConcept C42219234 @default.
- W2077579743 hasConcept C71924100 @default.
- W2077579743 hasConcept C99508421 @default.
- W2077579743 hasConceptScore W2077579743C118552586 @default.
- W2077579743 hasConceptScore W2077579743C142724271 @default.
- W2077579743 hasConceptScore W2077579743C16568411 @default.
- W2077579743 hasConceptScore W2077579743C1862650 @default.
- W2077579743 hasConceptScore W2077579743C204787440 @default.
- W2077579743 hasConceptScore W2077579743C27081682 @default.
- W2077579743 hasConceptScore W2077579743C2776750294 @default.
- W2077579743 hasConceptScore W2077579743C2777478456 @default.
- W2077579743 hasConceptScore W2077579743C2991744798 @default.
- W2077579743 hasConceptScore W2077579743C42219234 @default.
- W2077579743 hasConceptScore W2077579743C71924100 @default.
- W2077579743 hasConceptScore W2077579743C99508421 @default.
- W2077579743 hasIssue "12" @default.
- W2077579743 hasLocation W20775797431 @default.
- W2077579743 hasLocation W20775797432 @default.
- W2077579743 hasLocation W20775797433 @default.
- W2077579743 hasLocation W20775797434 @default.
- W2077579743 hasOpenAccess W2077579743 @default.
- W2077579743 hasPrimaryLocation W20775797431 @default.
- W2077579743 hasRelatedWork W1825083023 @default.
- W2077579743 hasRelatedWork W1973788946 @default.
- W2077579743 hasRelatedWork W1998267768 @default.
- W2077579743 hasRelatedWork W2029338556 @default.
- W2077579743 hasRelatedWork W2029595472 @default.
- W2077579743 hasRelatedWork W2045662349 @default.
- W2077579743 hasRelatedWork W2057193082 @default.
- W2077579743 hasRelatedWork W2066861358 @default.
- W2077579743 hasRelatedWork W2095244037 @default.
- W2077579743 hasRelatedWork W2894936748 @default.
- W2077579743 hasVolume "71" @default.
- W2077579743 isParatext "false" @default.
- W2077579743 isRetracted "false" @default.
- W2077579743 magId "2077579743" @default.
- W2077579743 workType "article" @default.